Core Viewpoint - The company expects to achieve a revenue of 5.2 billion yuan in 2025, representing a year-on-year increase of 46.15% [1] - The projected net profit attributable to shareholders is 2.15 billion yuan, reflecting a year-on-year increase of 50.37% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be 2 billion yuan, with a year-on-year increase of 46.95% [1] Revenue Growth Drivers - The growth in performance is primarily attributed to the successful promotion of commercialized products in the field of precision treatment for lung cancer [1] - Support from national medical insurance policies has contributed to the continuous growth of sales revenue for core products [1] - The optimization of resource allocation and the synergistic effects between products have also driven the improvement in operational performance [1]